Clinical Trial Update: Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a 12-month treatment with secukinumab in plaque psoriasis. The study assessed skin response and biomarkers and is reported as completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Psoriasis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriasis, Plaque-type Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2016-01-05